

DAFTAR PUSTAKA

1. International Agency for Research in Cancer. Cancer Facts and Figure 2018 Special Section: Ovarian Cancer. 2018.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics. *CA Cancer J Clin* 2019;60:277-300
3. Indonesian Society of Gynecologic Oncology (INASGO), National Data 2018-2019
4. Rescigno P, Cerillo I, Ruocco R, Condello C, De Placido S, Pensabene M. New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. *Biomed Res Int*. 2019.
5. American Cancer Society. Ovarian Cancer Causes, Risk Factors and Prevention. 2020.
6. Chang, L.C., Huang, C.F., Lai, M.S., Shen, L.J., Wu, F.L.L. and Cheng, W.F. Prognostic factors in epithelial ovarian cancer: A population-based study. *PloS one*.2018. 13(3), p.e0194993.
7. Center for Disease Control and Prevention (CDC). 2014. U.S. United States Cancer Statistics: 1999–2014 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. Didapat dari <https://nccd.cdc.gov/uscs/> diakses tanggal 2 Oktober 2020.
8. Hoffman BL, Scherge JO, Halvorson LM, Hamid CA, Corton MM, Schaffer JI. 2020. *Willams Gynecology*. 4th ed. New York: Mc-Graw Hall Education.
9. Hanahan, D. Weinberg, R. A. Hallmarks of Cancer: The next Generation. *Cell* 2011, 144 (5), 646–674.
10. Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer : An Updated Evidence Review for the U.S Preventive Services Task Force. Rockville (MD):Agency for Healthcare Research and Quality (US); 2018 Feb. (Evidence Synthesis, No. 157) Chapter 1, Introduction

11. Lombardo. Clinics in Surgery Peritoneal Cancer Indexes in Ovarian Carcinomatosis: Correlation between CT and Intraoperative Results and. 2018;1:1-6.
12. Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P. Ovarian cancer, the revised FIGO staging system, and the role of imaging. *Am J Roentgenol.* 2020;206(6):1351- 1360. doi:10.2214/AJR.15.15199
13. Jónsdóttir B, Lomnytska M, Poromaa IS, Silins I, Ståhlberg K. The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer. *Ann Surg Oncol.* Published online 2020:244- 251. doi:10.1245/s10434-020-08649-6
14. World Cancer Research Fund, American Institute For Cancer Research. Continuous Update Project. Ovarian Cancer 2019 Report.
15. SEER Stat Fact Sheets: Ovary Cancer. National Cancer Institute. 2014 <http://seer.cancer.gov/statfacts/html/ovary.html>
16. Hatano Y, Hatano K, Tamada M, et al. Comprehensive review of ovarian serous carcinoma. *Adv Anat Pathol.* 2019; 26(5): 329-36.
17. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in pathophysiology of ovarian cancer and implications for screening and prevention. *American Journal of Obstetrics and gynecology.* 2015: 262-6.
18. Shabir S, Gill PK. Global scenario on ovarian cancer- Its dynamics, relative survival, treatment, and epidemiology. *Adesh University Journal of Medical Sciences and Research.* 2020; 2(1): 17-22.
19. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. *Annals of Oncology.* 2013; 24(10): 7-10.
20. Gharwan H, Bunch KP, Annunziata CM. The role of reproductive hormones in epithelial ovarian carcinogenesis. *Endocrine-Related Cancer.* 2020; 22(6): 339-63.
21. Rampersad AC, Wang Y, Smith ER, Xu X. Menopause and ovarian cancer risk: mechanism and experimental support. *Am J Clin Exp Obstet Gynecol.* 2019; 2(1): 14-23.

22. Aljohani AM. Hormonal imbalance and ovarian cancer. *International Journal of Scientific and Engineering Research*. 2018; 8(11): 282-86.
23. Herawati S. Anti-Mullerian Hormone (AMH) as a Novel Marker for Ovarian Function: A Review. *Bali Medical Journal*. 2019; 8(2): 384-90.
24. Mendez C, Morales F, Gomora MJ, Calvillo A, Lopez H, Pedernera E. Sexual Steroids in Epithelial Ovarian Cancer. *SMGroup*. 2019. 1-8.
25. Furuya, Mitsuko. Ovarian Cancer Stroma : Pathophysiology and the Roles in Cancer Development. 18 July 2012. *Cancers Journal*:4. Pg 701-724
26. Hirst J, Crow J, Godwin A. Ovarian Cancer Genetics: Subtypes and Risk Factor. *IntechOpen*. 2018:1-38
27. Budiana NG, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *Journal of Turkish German Gynecological Association*. 2019; 20: 47-54
28. Longuespee R, Boyon C, Annie Desmons, et al. Ovarian cancer molecular pathology. *Cancer Metastasis Rev*. 2020: 1-14
29. Voutsadakis IA. Hormone receptors in serous ovarian carcinoma: Prognosis, pathogenesis, and treatment considerations. *Clinical Medicine Insights: Oncology*. 2021; 10: 17-25.
30. Chen L, Liu X, Zhang J, et al. Characterization of desmoglein 2 expression in ovarian serous kankers and its prognostic significance in high-grade serous carcinoma. *Int J Clin Exp Pathol*. 2018; 11(10): 4977-86.
31. Gharwan H, Bunch KP, Annunziata CM. The role of reproductive hormones in epithelial ovarian carcinogenesis. *Endocrine-Related Cancer*. 2022; 22(6): 339-63.
32. Mulisyah O, Sikakulya FK, Mastaki M, Gertrude T, Jeff M. The Challenges of Managing Ovarian Cancer in the Developing World. *Case Rep Oncol Med*. 2020;2020:1-4. doi:10.1155/2020/8379628
33. Ghisoni E, Katsaros D, Maggiorotto F, et al. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: A two- centers experience. *J Ovarian Res*. 2018;11(1):1-7. doi:10.1186/s13048-018-0415-y
34. Yakushiji M. Surgical treatment of ovarian cancer. *Gan No Rinsho*.

- 1990;36(10):1167- 1173. doi:10.5772/53972
35. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 1.2019 featured updates to the nccn guidelines. *JNCCN J Natl Compr Cancer Netw.* 2019;17(8):896-909. doi:10.6004/jnccn.2019.0039
36. Lombardo. *Clinics in Surgery Peritoneal Cancer Indexes in Ovarian Carcinomatosis: Correlation between CT and Intraoperative Results and.* 2019;1:1-6.
37. Gorodnova TV, Sokolenko AP, Kuligina E, Berlev IV, Imyatnov EN. Principles of clinical management of ovarian cancer. *Chin Clin Oncol.* 2018; 7(6): 1-5
38. I. B. Rumbawa Pamaron, "Perbedaan Kadar Cancer Antigen-125 dan Human Epididimis-4 Pada Kanker Ovarium Tipe Epitelial Stadium I, Stadium II dan Stadium III," Program Pendidikan Dokter Spesialis I FK UNUD / RSUP Sanglah Denpasar, Denpasar, 2020
39. American Cancer Society. Prostate Cancer Early Detection , Diagnosis , and Staging Can Ovarian Cancer Be Found Early ? *Am Cancer Soc.* Published online 2021:1-25. <https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging.html>
40. Braat DDM. Diagnosis and management of ovarian disorders. *Eur J Obstet GynecolReprod Biol.* 2019;72(2):217. doi:10.1016/s0301-2115(96)02679-6
41. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 1.2019 featured updates to the nccn guidelines. *JNCCN J Natl Compr Cancer Netw.*2019;17(8):896-909. doi:10.6004/jnccn.2019.0039
42. Trihandini I, Nurrika D. Analisis Ketahanan Hidup Penderita Kanker Ovarium Epithelial di RS Dharmais Jakarta. *J Kesehat Masy Nas Vol 5, No 3, Desember 20190.* 2010;5:139-144
43. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J Turkish-German Gynecol Assoc.* 2019;20(1):47-54. doi:10.4274/jtgga.galenos.2018.2018.0119
44. Koshiyama M, Matsumura N, Konishi I. Recent Concepts of Ovarian Cancinogenesis: Type I and Tipe II. *BioMed research International.* 2020; 1-11
45. Suppiah, Subapriya. The Past, Present, and Future of Diagnostic Imaging in

46. Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P. Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. *AJR* 2018;206:pg 1-10
47. <https://www.iotagroup.org/iota-models-software/iota-simple-rules-and-srrisk-calculator-diagnose-ovarian-cancer>
48. Dakhly DMR, Gaafar HM, Sediek MM, Ibrahim MF, Momtaz M. Diagnostic Value of the International Ovarian Tumor Analysis (IOTA) Simple Rule Versus Pattern Recognition to Differentiate Between Malignant and Benign Ovarian Masses. September 2019. *Int J Gynecol Obstet* 2019; Pg. 1-6
49. Doufekas K and Olaitan A, "Clinical Epidemiology of Epithelial Ovarian Cancer in the UK," *Int J Womens Heal*, vol. 6, pp. 537–545, 2020
50. S. H. L. George, R. Garcia, and B. M. Slomovitz, "Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention," *Front. Oncol.*, vol. 6, May 2022, doi: 10.3389/fonc.2016.00108
51. Chesnais M, Lecuru F, Mimouni M, Ngo C, Fauconnier A, Huchon C. A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer. *PLoS One*. 2021 Nov8;12(11):e0187245. doi: 10.1371/journal.pone.0187245. PMID: 29117194; PMCID: PMC5678871.
52. Chesnais M, Lecuru F, Mimouni M, Ngo C, Fauconnier A, Huchon C. A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer. *PLoS One*. 2022 Nov8;12(11):e0187245. doi: 10.1371/journal.pone.0187245. PMID: 29117194; PMCID: PMC5678871.
53. Tentes AAK, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. *EJSO Eur J Surg Oncol*. 2021;29:69–73
54. Hural O, Mylyan Y, Fetsych M, et al. The efficiency of ct at pre-operative evaluation stage of PCI in patients with recurrent ovarian cancer. *Int J Radiol Radiat Ther*. 2019;4(2):349-352. DOI: 10.15406/ijrrt.2017.04.00092
55. Ovarian cancer risks and causes [webpage on the Internet] London: Cancer Research UK; 2021. [Accessed January 10, 2022]. [updated November 29,

- 2022]. Available from: <http://www.cancerresearchuk.org/cancer-help/type/ovarian-cancer/about/ovarian-cancer-risks-and-causes>.
56. Doufekas K, Olaitan A. Clinical epidemiology of epithelial ovarian cancer in the UK. *Int J Womens Health*. 2014;6:537-545. Published 2014 May 23. doi:10.2147/IJWH.S40894
 57. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. *Gynecol Oncol*. 2019;129(1):258–264.
 58. Chan J, Urban R, Cheung M, et al. Ovarian cancer in younger vs older women: a population-based analysis. *Br J Cancer*. 2020;95(10):1314.
 59. Mohammadian M, Ghafari M, Khosravi B, et al. Variations in the incidence and mortality of ovarian cancer and their relationship with the human development index in European Countries in 2012. *Biomed Res Ther*. 2018;4(08):1541–1557.
 60. Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE. Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. *BMC Cancer*. 2018;18(1):1039.
 61. Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. *PLoS One*. 2018;13(10):e0205000.
 62. Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. *Cancer*. 2018;77(6):1131–1136.
 63. Poole EM, Merritt MA, Jordan SJ, et al. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. *Cancer Epidemiol Prev Biomarkers*. 2020.
 64. Ries LA. Ovarian cancer. Survival and treatment differences by age. *Cancer*. 2021;71(2 Suppl):524–529.
 65. Ørskov M, Iachina M, Guldberg R, Mogensen O, Nørgård BM. Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study. *BMJ Open*. 2019;6(4):e010123
 66. Bandera EV, Lee VS, Qin B, Rodriguez-Rodriguez L, Powell CB, Kushi LH. Impact of body mass index on ovarian cancer survival varies by stage. *Br J Cancer*. 2019;117(2):282–289.

67. Delort L, Kwiatkowski F, Chalabi N, Satih S, Bignon YJ, Bernard-Gallon DJ. Central adiposity as a major risk factor of ovarian cancer. *Anticancer Res.* 2019;29(12):5229–5234.
68. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2022;11(9):822–828.
69. Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: the Iowa Women's Health Study. *Cancer.* 2019;100(7):1515–1521.
70. Kotsopoulos J, Moody JR, Fan I, et al. Height, weight, BMI and ovarian cancer survival. *Gynecol Oncol.* 2021;127(1):83–87.
71. Beehler GP, Sekhon M, Baker JA, et al. Risk of ovarian cancer associated with BMI varies by menopausal status. *J Nutr.* 2006;136(11):2881–2886.
72. Leitzmann MF, Koebnick C, Danforth KN, et al. Body mass index and risk of ovarian cancer. *Cancer.* 2019;115(4):812–822.
73. Kim SJ, Rosen B, Fan I, et al. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. *Br J Cancer.* 2018;116(7):964.
74. Huang T, Eliassen AH, Hankinson SE, et al. A prospective study of leisure-time physical activity and risk of incident epithelial ovarian cancer: impact by menopausal status. *Int J Cancer.* 2021;138(4):843–852.
75. Xie WT, Wang YQ, Xiang ZS, et al. Efficacy of IOTA simple rules, O-RADS, and CA-125 to distinguish benign and malignant adnexal masses. *J Ovarian Res.* 2022;15(1):15.
76. Crestani A, Theodore C, Levailant JM, Thomassin-Naggara I, Skalli D, Miailhe G, et al. Magnetic resonance and ultrasound fusion imaging to characterise ovarian masses: a feasibility study. *Anticancer Res.* 2021;40(7):4115–4121.
77. What Are IOTA Easy Descriptors and Simple Rules: How to Use Them. *Ultrasound Med. Biol.* 2019;45:S19.
78. Tantipalakorn C., Wanapirak C., Khunamornpong S., Sukpan K., Tongsong T. IOTA Simple Rules in Differentiating between Benign and Malignant Ovarian Tumors. *Asian Pac. J. Cancer Prev. APJCP.* 2019;15:5123–5126.

79. Nunes N., Ambler G., Foo X., Naftalin J., Widschwendter M., Jurkovic D. Use of IOTA Simple Rules for Diagnosis of Ovarian Cancer: Meta-Analysis. *Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol.* 2021;44:503–514.
80. Auekitrungrueng R., Tinnangwattana D., Tantipalakorn C., Charoenratana C., Lerthiranwong T., Wanapirak C., Tongsong T. Comparison of the Diagnostic Accuracy of International Ovarian Tumor Analysis Simple Rules and the Risk of Malignancy Index to Discriminate between Benign and Malignant Adnexal Masses. *Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet.* 2019;146:364–369.
81. Piovano E., Cavallero C., Fuso L., Viora E., Ferrero A., Gregori G., Grillo C., Macchi C., Mengozzi G., Mitidieri M., et al. Diagnostic Accuracy and Cost-Effectiveness of Different Strategies to Triage Women with Adnexal Masses: A Prospective Study. *Ultrasound Obstet. Gynecol.* 2019;50:395–403.
82. Phinyo P, Patumanond J, Saenrungmuaeng P, et al. Diagnostic Added-Value of Serum CA-125 on the IOTA Simple Rules and Derivation of Practical Combined Prediction Models (IOTA SR X CA-125). *Diagnostics (Basel).* 2021;11(2):173.
83. Kaijser J., Bourne T., Valentin L., Sayasneh A., Van Holsbeke C., Vergote I., Testa A.C., Franchi D., Van Calster B., Timmerman D. Improving Strategies for Diagnosing Ovarian Cancer: A Summary of the International Ovarian Tumor Analysis (IOTA) Studies. *Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol.* 2020;41:9–20.
84. Al-Musalhi K., Al-Kindi M., Ramadhan F., Al-Rawahi T., Al-Hatali K., Mula-Abed W.-A. Validity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian Cancer. *Oman Med. J.* 2021;30:428–434.
85. Dikmen Z.G., Colak A., Dogan P., Tuncer S., Akbiyik F. Diagnostic Performances of CA-125, HE4, and ROMA Index in Ovarian Cancer. *Eur. J. Gynaecol. Oncol.* 2017;36:457–462.
86. Liao X.-Y., Huang G.-J., Gao C., Wang G.-H. A Meta-Analysis of Serum Cancer Antigen 125 Array for Diagnosis of Ovarian Cancer in Chinese. *J. Cancer Res. Ther.* 2014;10:C222–C224. doi: 10.4103/0973-1482.145884.

87. Huy N.V.Q., Van Khoa V., Tam L.M., Vinh T.Q., Tung N.S., Thanh C.N., Chuang L. Standard and Optimal Cut-off Values of Serum ca-125, HE4 and ROMA in Preoperative Prediction of Ovarian Cancer in Vietnam. *Gynecol. Oncol. Rep.* 2018;25:110–114.
88. Hural O, Mylyan Y, Fetsych M, et al. The efficiency of ct at pre-operative evaluation stage of PCI in patients with recurrent ovarian cancer. *Int J Radiol Radiat Ther.* 2017;4(2):349-352.
89. Jónsdóttir B, Lomnytska M, Poromaa IS, Silins I, Stålberg K. The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer. *Ann Surg Oncol.* 2021;28(1):244-251.
90. Bhatt A, Mehta S. Cytoreductive surgery for peritoneal metastases: principles and techniques. In: Bhatt A, editor. *Management of peritoneal metastases cytoreductive surgery, HIPEC and beyond.* Singapore: Springer; 2018.
91. Seshadri RA, Hemanth Raj E. Diagnostic laparoscopy in the pre-operative assessment of patients undergoing cytoreductive surgery and HIPEC for peritoneal surface malignancies. *Indian J Surg Oncol.* 2019;7(2):230–235.
92. Chereau E, Ballester M, Selle F, Cortez A, Darai E, Rouzier R. Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. *Am J Obstet Gynecol.* 2019;202:178e1–e10.
93. Duhr CD, Kenn W, Kickuth R, Kerscher AG, Germer CT, Hahn D, W Pelz JO. Optimizing of preoperative computed tomography for diagnosis in patients with peritoneal carcinomatosis. *World J Surg Oncol.* 2011;9:171.
94. Rosendahl M, Harter P, Bjorn SF, Hogdall C. Specific regions, rather than the entire Peritoneal Carcinosis Index, are predictive of complete resection and survival in advanced epithelial ovarian cancer. *Int J Gynecol Cancer.* 2018;28:316–22.
95. Fischerova D, Burgetova A. Imaging techniques for the evaluation of ovarian cancer. *Best Pract Res Clin Obstet Gynaecol.* 2014;28:697–720.
96. Lluca A, Serra A, Rivadulla I, Gomez L, Escrig J, group Mw. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index. *World J Surg Oncol.* 2020;16:37.

97. Lampe B, Kroll N, Piso P, Forner DM, Mallmann P. Prognostic significance of Sugarbaker's Peritoneal Cancer Index for the operability of ovarian carcinoma. *Int J Gynecol Cancer*. 2022;25:135–144.
98. Tentes AAK, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. *EJSO Eur J Surg Oncol*. 2021;29:69–73.
99. Elzarkaa AA, Shaalan W, Elemam D, Mansour H, Melis M, Malik E, et al. Peritoneal Cancer Index as a predictor of survival in advanced-stage serous epithelial ovarian cancer: a prospective study. *J Gynecol Oncol*. 2018;29:e47.
100. Fotopoulou C, Jones BP, Savvatis K, Campbell J, Kyrgiou M, Farthing A, et al. Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities. *Arch Gynecol Obstet*. 2019;294:607–614.
101. Passot G, Dumont F, Goéré D, Arvieux C, Rousset P, Regimbeau JM, et al. Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE) *Br J Surg*. 2018;105:663–667.
102. van de Vrie R, Rutten MJ, Asseler JD, Leeftang MM, Kenter GG, Mol BWJ, et al. Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. *Cochrane Database Syst Rev*. 2019;3:CD009786

